Engineered proteins from transgenic animals
来自转基因动物的工程蛋白质
基本信息
- 批准号:8469521
- 负责人:
- 金额:$ 77.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-01-01 至 2014-04-30
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAntibodiesAntibody AffinityAntibody FormationAntigensAutoimmunityB-LymphocytesBiotechnologyBirdsBreedingCell LineCellsChickensComplementarity Determining RegionsDataDevelopmentEngineeringEpitopesEvaluationFramework RegionsGene ConversionGenomeGenomicsHomologous GeneHumanHuman EngineeringIGH@ gene clusterImmunizationImmunoglobulin GenesIn VitroIndustryIntegraseKnock-in MouseKnock-outLightLymphoid CellMalignant NeoplasmsMethodsModificationMonoclonal AntibodiesMusOryctolagus cuniculusOutcomePhasePhylogenetic AnalysisPositioning AttributeProcessPropertyProtein EngineeringProteinsPseudogenesRandomizedResearchRouteSerineSiteSourceSpecificityTechnologyTestingTherapeuticTherapeutic Monoclonal AntibodiesTherapeutic antibodiesTimeTissuesTransgenic AnimalsTransgenic OrganismsTryptophanTyrosineWorkantibody engineeringbasecost effectivehuman diseasehuman monoclonal antibodiesimprovedlarge scale productionmeetingsnovelprotein protein interactionresearch studytransmission processvector
项目摘要
DESCRIPTION (provided by applicant): Approximately 25% of the products being developed by the biotechnology industry are antibodies and many of these antibodies are directed to epitopes on human cells and tissues. We are proposing a novel concept for the production of antibodies with therapeutic potential that is based on recent advances in protein-protein interactions and recent developments in transgenic technology. Execution of this concept will obviate many of the expensive and time consuming modifications that are frequently required after potentially therapeutic monoclonal antibodies are identified in order to optimize their pharmacological properties and to make them amenable to large scale production. By combining recent data derived from in vitro studies with the nascent understanding of genomics, we will extend the range of epitopes that can be accessed and, therefore, extend the range of potentially therapeutic antibodies.
描述(由申请人提供):生物技术行业正在开发的产品中约有25%是抗体,其中许多抗体针对人体细胞和组织上的表位。我们提出了一个新的概念,用于生产具有治疗潜力的抗体,这是基于蛋白质-蛋白质相互作用的最新进展和转基因技术的最新发展。这个概念的实施将避免许多昂贵和耗时的修饰,这些修饰在鉴定出潜在的治疗性单克隆抗体之后经常需要,以便优化它们的药理学性质并使它们适合于大规模生产。通过将来自体外研究的最新数据与对基因组学的新生理解相结合,我们将扩大可以获得的表位范围,从而扩大潜在治疗性抗体的范围。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Philip Leighton其他文献
Philip Leighton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Philip Leighton', 18)}}的其他基金
Human immunotherapeutics for Biodefense Applications
用于生物防御应用的人体免疫治疗
- 批准号:
6739376 - 财政年份:2004
- 资助金额:
$ 77.58万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 77.58万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 77.58万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 77.58万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 77.58万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 77.58万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 77.58万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 77.58万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 77.58万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 77.58万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 77.58万 - 项目类别: